Predict your next investment

3L company logo
Venture Capital
FINANCE | Investment Firms & Funds
3lcap.com

See what CB Insights has to offer

Investments

33

Funds

4

About 3L

3L Capital is an investment firm based in Los Angeles and NYC providing expansion capital to companies in the technology, media, and consumer sectors.

3L Headquarters Location

1100 Glendon Avenue, PH1

Los Angeles, California, 90024,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

3L Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

3L Rank

Research containing 3L

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned 3L in 1 CB Insights research brief, most recently on Oct 7, 2019.

Latest 3L News

Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma

Jul 6, 2022

Search jobs 06-Jul-2022 Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma 2022-07-05 21:26 GMT+02 Oslo, Norway, 5 July 2022 Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma (3L R and R FL). Following a comprehensive review and independent data evaluation of PARADIGME and a subsequent request for regulatory agency interaction, the Board of Directors (Board) has taken the difficult decision to discontinue the study. No further patients will be enrolled into PARADIGME. The PARADIGME trial enrolled a total of 109 patients. The Company will now ensure a wind-down of PARADIGME in a structured manner ensuring patients receive the best possible care during this period. While Betalutin®, at the selected dose of 15 MBq/kg after a pre-dose of 40 mg lilotomab (40/15), has continued to display an attractive safety profile and positive signs of efficacy in some patients, the Board considers that the observed profile does not fully meet the objectives set out for the PARADIGME study. Only one out of three patients responded to the treatment with the average duration of the response of approximately six months. As a result, the Board is of the opinion that the demonstrated profile is no longer sufficiently competitive to bring Betalutin® to the market in the third line relapsed and refractory FL indication, within a timeframe that makes financial and commercial sense for the Company. The Company still believes there could be a market for Betalutin® in light of its safety profile, promising efficacy in earlier lines of therapy and unique feature of being delivered as a one-time dose. However, a potential new development programme would need to be conducted in a different patient population and line of treatment. The Company will therefore explore potential partnerships and will also seek advice from the US Food and Drug Administration (FDA) to discuss if there could be a possible way forward for Betalutin® in an alternative setting. The Company will now focus its efforts and resources on developing its pipeline of proprietary CD37-targeting products from which Nordic Nanovector believes it can create value for shareholders over the longer term. These pipeline opportunities include: ·     Humalutin®, a radioimmunotherapy candidate based on a chimeric anti-CD37 antibody and the beta-emitting radionuclide lutetium-177 for non-Hodgkin lymphoma (NHL). ·     Alpha37, an alpha-emitting radioimmunotherapy candidate based on a chimeric anti-CD37 antibody conjugated to lead-212, currently being explored with partner OranoMed for relapsed/refractory chronic lymphocytic leukaemia. ·     A portfolio of fully humanized anti-CD37 antibodies with potential in haematological cancers and autoimmune diseases. ·     A CD37 DOTA CAR-T cell opportunity in haematological cancers, which is the subject of a research collaboration with the University of Pennsylvania. Following the decision to discontinue PARADIGME, the Board has also decided to implement a restructuring of the Company with immediate effect with the purpose of reducing costs where necessary to enable support of essential activities associated with development of the pipeline. The Company's cash position at the end of Q2 2022 was approximately NOK 280m (end of Q1 NOK 356.3m). Full Q2 results will now be reported on 31 August. Chairman, Jan H. Egberts commented: "The decision to discontinue PARADIGME is extremely disappointing not only for the Nordic Nanovector team, but also for patients, healthcare providers and our shareholders as there continues to be an unmet medical need in frail and elderly patients with Follicular Lymphoma. The new independently reviewed data from PARADIGME, in an increasingly competitive market and with the slow speed of recruitment makes progressing PARADIGME further very difficult. Consequently, the Board no longer sees a viable path to commercialisation in the current indication that would make sense for the Company and its shareholders. We are extremely grateful to all the clinical investigators and patients who have participated in PARADIGME. CEO, Erik Skullerud commented: Our focus will now shift to our pipeline of other CD37-targeting assets, which give us multiple shots on goal, including Humalutin®, Alpha37, a portfolio of fully humanized anti-CD37 antibodies and the CD37 CAR-T. We look forward to communicating our development plans for these assets in more detail in the coming months." Nordic Nanovector will host a webcast at 08.30 CEST on Wednesday 6 July, elaborating on the strategic decision to stop PARADIGME and including a Q&A session. To join the webcast please sign up via our website www.nordicnanovector.com . For further information, please contact: IR enquiries

3L Investments

33 Investments

3L has made 33 investments. Their latest investment was in Metropolis as part of their Series B on June 6, 2022.

CBI Logo

3L Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/15/2022

Series B

Metropolis

$167M

Yes

5

2/2/2022

Series B

Crisp

$35M

Yes

9

1/6/2022

Series F

dunzo

$240M

No

45

12/15/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

12/7/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/15/2022

2/2/2022

1/6/2022

12/15/2021

12/7/2021

Round

Series B

Series B

Series F

Series B

Series B

Company

Metropolis

Crisp

dunzo

Subscribe to see more

Subscribe to see more

Amount

$167M

$35M

$240M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

9

45

10

10

3L Fund History

4 Fund Histories

3L has 4 funds, including 3L Capital I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/6/2020

3L Capital I

Late-Stage Venture Capital

Closed

$211.57M

4

3/29/2019

3L Capital RO

$99M

10

11/7/2018

3L Capital SDC

$99M

0

3L Capital II

10

Closing Date

4/6/2020

3/29/2019

11/7/2018

Fund

3L Capital I

3L Capital RO

3L Capital SDC

3L Capital II

Fund Type

Late-Stage Venture Capital

Status

Closed

Amount

$211.57M

$99M

$99M

Sources

4

10

0

10

3L Team

3 Team Members

3L has 3 team members, including current Founder, Managing Partner, Shawn Colo.

Name

Work History

Title

Status

Shawn Colo

Leaf Group, and Spectrum Equity

Founder, Managing Partner

Current

David Leyrer

Boulevard Capital Partners, and Nexus Group

Founder, Managing Partner

Current

Brian Cooper

Chief Financial Officer

Former

Name

Shawn Colo

David Leyrer

Brian Cooper

Work History

Leaf Group, and Spectrum Equity

Boulevard Capital Partners, and Nexus Group

Title

Founder, Managing Partner

Founder, Managing Partner

Chief Financial Officer

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.